The FDA has cleared a trial of ER-100 from Life Biosciences for eye rejuvenation. In the trial, ER-100 will deliver inducible expression of the three reprogramming factors. Oct-4, Sox-2, and Klf-4 are colloquially known together as OSK. This trial is an extension of the work of Harvard professor and longevity enthusiast David Sinclair. The hypothesis here […]
The post FDA OKs risky, pioneering OSK rejuvenation trial with Sinclair’s ER-100 appeared first on The Niche.